Tesla's sales decline in Europe continues despite new lower-cost models, while industry buzz swirls around a hotly denied report of potential Ford-Xiaomi collaboration. Meanwhile, U.S. dealers show surprising pragmatism toward the EV transition.
After years of share price weakness, Immunocore Holdings (IMCR) appears significantly undervalued by traditional metrics. But does the market know something the models don't? We examine the DCF and P/S analyses, the company's unique T-cell receptor platform, and the risks that have kept investors wary.
Alibaba Group is making a massive, multi-billion yuan bet to integrate its Qwen AI assistant across its ecosystem and develop its own AI chips, signaling a strategic pivot to reduce foreign dependency and deepen user engagement amid intense competition.
Toyota Motor Corp. has cemented its position as the world's top-selling automaker for 2025, posting record global sales fueled by robust demand for its hybrid vehicles. The results underscore the company's strategic bet on a multi-pathway approach to electrification, even as new U.S. tariffs and shifting trade policies challenge the global industry.
While Procter & Gamble's stock has trailed the market over the past year, analysts remain cautiously optimistic. The company's latest earnings reveal a story of resilience amid pricing pressures and shifting consumer demand, leaving investors to weigh its steady guidance against a recent analyst downgrade.
Equinor's stock has gained ground over the past month, yet a detailed fair value analysis suggests the Norwegian energy giant may be trading at a premium. Investors are weighing strong long-term momentum against future headwinds from the green shift.
Shoppers are bracing for another wave of price increases as new import taxes take effect, targeting a range of everyday items from spirits to seafood. Experts warn the hikes will squeeze household budgets and force tough choices at the supermarket.
Shares of clinical-stage biotech Scholar Rock (NASDAQ: SRRK) have surged nearly 60% in three months, closing at $44.34. This rally, backed by promising clinical progress, has investors weighing its premium valuation against its long-term potential in treating serious diseases.
Russian pipeline gas exports to Europe via TurkStream increased in January, even as the EU finalizes a sweeping ban and Moscow's overall sales hit a multi-decade low, underscoring the continent's complex and uneven energy transition.
The Norwegian monarchy is rocked by dual crises as Marius Borg Høiby, son of Crown Princess Mette-Marit, stands trial on serious criminal charges, while newly unsealed Jeffrey Epstein documents reveal extensive past connections to the princess.
In a joint diplomatic push, Chile, Brazil, and Mexico have officially submitted former Chilean President Michelle Bachelet's candidacy to become the first woman to lead the United Nations, as the race to succeed Antonio Guterres heats up.
With the FIFA World Cup in North America, the Milano Cortina Winter Olympics, and a packed calendar of major events, 2026 is poised to be a landmark year for sports. Brands and retailers are deploying sophisticated strategies that prioritize cultural marketing and community engagement over mere sales spikes, navigating a landscape where consumer loyalty is won through storytelling, not just sponsorship.
The Vatican has launched a meticulous three-month restoration of Michelangelo's iconic 'Last Judgment' fresco in the Sistine Chapel, aiming to revive the masterpiece's original chromatic brilliance obscured by decades of grime.
A highly sensitive whistleblower complaint alleging misconduct by Director of National Intelligence Tulsi Gabbard has been locked within the intelligence bureaucracy since May, with Congress aware of its existence but blocked from reviewing it amid accusations of obstruction.
Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.
While reports surface of potential delays for AMD's next-generation MI450 AI accelerators, major analysts reaffirm bullish price targets, highlighting strong long-term demand and the stock's 100% surge over the past year.
With gold and silver hitting record highs amid market turbulence, numismatic experts argue that certified rare coins offer a unique blend of tangible value, historical significance, and surprising liquidity for discerning investors.
As XRP hovers around $2, a stark divide emerges between institutional and algorithmic forecasts for its 2026 value. Standard Chartered's bullish $8 target contrasts with more cautious AI projections, with the outcome likely hinging on ETF inflows, regulatory clarity, and real-world adoption.
As tech giants design their own AI processors, Broadcom's design expertise and TSMC's manufacturing might are creating a lucrative second front in the semiconductor boom, diversifying the winners beyond the GPU market leader.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
